ZEALAND PHARMA AS
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1998-01-01
- Employees
- 150
- Market Cap
- $9.1B
Augustine Therapeutics Appoints Rie Schultz Hansen as CSO, Establishes Copenhagen Subsidiary to Advance HDAC6 Inhibitor Pipeline
Augustine Therapeutics has appointed Rie Schultz Hansen, PhD, as Chief Scientific Officer to lead the advancement of lead candidate AGT-100216 through Phase I/II clinical trials for Charcot-Marie-Tooth disease.
Zealand Pharma Considers Accelerating Obesity Drug Launch Following Landmark Roche Partnership
Zealand Pharma CEO Adam Steensberg has indicated that the company's obesity drug candidate petrelintide could reach the market earlier than planned following a strategic partnership with Roche.
Zealand Pharma Appoints Utpal Singh as CSO to Advance Peptide Therapeutics for Obesity
Zealand Pharma has appointed Utpal Singh as Chief Scientific Officer to lead discovery research and translational sciences, bringing nearly 25 years of pharmaceutical industry experience to the company.
Ironwood Pharmaceuticals Faces Setback in Apraglutide Development for Short Bowel Syndrome
Ironwood Pharmaceuticals has announced that a confirmatory Phase 3 trial will be required for apraglutide in short bowel syndrome with intestinal failure, following its $1 billion acquisition of VectivBio.
Roche and Zealand Pharma Forge $5.3 Billion Partnership to Develop Novel Obesity Treatments
Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.
Boehringer Ingelheim Advances Dual-Action Obesity Drug Survodutide to Phase 3 Trials
Boehringer Ingelheim and Zealand Pharma have initiated three phase 3 trials for survodutide, a glucagon/GLP-1 receptor dual agonist that achieved up to 19% weight loss in phase 2 studies.
GI Advances: FDA Approvals, Novel Research Shape Gastroenterology in Early 2025
The FDA approved mirikizumab (Omvoh) for Crohn's disease, marking its second approval in IBD after ulcerative colitis, based on positive Phase 3 trial results.
FDA Issues Complete Response Letter for Zealand Pharma's Glepaglutide in Short Bowel Syndrome
The FDA issued a Complete Response Letter for Zealand Pharma's glepaglutide, a GLP-2 analog, intended for short bowel syndrome (SBS) treatment, citing insufficient evidence of efficacy and safety.
Zealand Pharma and Eli Lilly Lead the Charge in Weight Loss Drug Development
Zealand Pharma's survodutide, a unique anti-obesity molecule, is currently in Phase 3 trials, potentially offering a more effective or tolerable alternative for weight loss.
Zealand Pharma's Petrelintide Enrolls First Participant in Phase 2b Obesity Trial
Zealand Pharma has initiated a Phase 2b trial (ZUPREME-1) for petrelintide, a long-acting amylin analog, in overweight or obese individuals.